Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Challenges in the diagnostics and treatment of ectopic ameloblastic carcinoma: a case report (CROSBI ID 296246)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Tarle, Marko ; Müller, Danko ; Tarle, Antonia ; Blivajs, Igor ; Aljinović Ratković, Narandža ; Knežević, Predrag Challenges in the diagnostics and treatment of ectopic ameloblastic carcinoma: a case report // Croatian medical journal, 61 (2020), 3; 271-275. doi: 10.3325/cmj.2020.61.271

Podaci o odgovornosti

Tarle, Marko ; Müller, Danko ; Tarle, Antonia ; Blivajs, Igor ; Aljinović Ratković, Narandža ; Knežević, Predrag

engleski

Challenges in the diagnostics and treatment of ectopic ameloblastic carcinoma: a case report

Ameloblastic carcinoma (AC) is a rare and aggressive malignant epithelial odontogenic tumor, most commonly located in the mandible or maxilla. An extremely rare extragnathic localization of AC with no connection to the jaws, ectopic ameloblastic carcinoma (EAC), has so far been described only three times. This report presents a 64-year-old male with skull base ameloblastic carcinoma and offers a review of diagnostic and treatment challenges related to EAC. Because of its rarity and histological similarity to other tumors, EAC is often misdiagnosed. This is why we established a pathohistological and immunohistochemical profile of EAC that differentiates it from histologically similar tumors. The most frequently used EAC treatment is radical surgical resection, but the majority of reviewed reports described local recurrence. Taking into consideration new scientific discoveries on the molecular pathogenesis of ameloblastoma, we are the first to have performed BRAF mutation analysis in an EAC patient. BRAF inhibitors offer promising results in the treatment of BRAF-positive ameloblastomas and should continue to be researched in AC and EAC patients. Finally, EAC should be considered in differential diagnosis of head and neck tumors outside the jaws

ectopic ameloblastic carcinoma ; skull base ; odontogenic tumor ; BRAF mutation

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

61 (3)

2020.

271-275

objavljeno

0353-9504

10.3325/cmj.2020.61.271

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost